Somatostatin discovery

Berk, S.C., Rohree, S.P., Degrado, S.J., Birzin, E.T., Mosley, R.T., Hutchins, S.M., Pasternak, A., Schaeffer, J.M., and Underwood, D.J. A combinatorial approach toward the discovery of non-peptide, subtype-selective somatostatin receptor ligands. /. Comb. Chem. 1999, 1, 388-396. 

Martin, R.F., Green, L.G., Guba, W., Kratochwil, N., and Christ, A. (2007) Discovery of the first nonpeptidic, small-molecule, highly selective somatostatin receptor subtype 5 antagonists a chemogenomics approach. Journal of Medicinal Chemistry, 50, 6291-6294. 

Octreotide (known clinically as Sandostatin0) is now used for treatment of gastro-enteropancreatic tumors, but its great affinity for somatostatin receptors, and the discovery that many neuroendocrine tumors profusely express these receptors, suggested its... 

---